ImmunityBio (NASDAQ: IBRX) Just Broke Out on a HUGE Catalyst Setup – Could Soar 36%-59% Higher

We flagged ImmunityBio, Inc. (NASDAQ: IBRX) in our breakout watchlist a few months back — and the stock has since resolved a multi-month symmetrical triangle to the upside on a +6.95% single-session surge and looks headed even higher.

As we’ll get to just ahead, the combination of accelerating commercial momentum behind its flagship cancer therapy, a major regulatory decision on the horizon that could meaningfully expand its market, and a fresh technical breakout makes IBRX one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

ImmunityBio is a San Diego–based biotech that develops next-generation immunotherapies — treatments designed to activate a patient’s own immune system to fight cancer and infectious diseases. Its lead product, ANKTIVA, is an FDA-approved therapy used in combination with BCG for a form of bladder cancer known as BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

In plain English, when a bladder-cancer patient stops responding to the standard BCG treatment and their doctor needs another proven, bladder-preserving option before considering surgical removal of the bladder, ANKTIVA is one of the newer FDA-approved therapies they can now turn to. IBRX’s business hinges on how quickly ANKTIVA scales in the U.S. bladder-cancer market, whether the FDA expands its approved use into broader patient populations, and how successfully the company builds out international commercial channels.

IBRX’s latest move reflects a powerful confluence of developments — commercial, regulatory, and strategic — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and IBRX is looking less like a speculative development-stage biotech and more like a commercially executing immunotherapy franchise with an accelerating U.S. revenue ramp, an internationally expanding footprint, and two potential FDA label expansions stacked up within the next six months.

The story is getting stronger by the quarter, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Symmetrical Triangle Pattern Breakout: IBRX is resolving a multi-month symmetrical triangle to the upside — the purple trendlines on the daily chart trace lower highs pressing down from the ~$12.50 March spike and higher lows building off the spring base, compressing price into an ever-tighter coil at the apex. That structure is a standoff between buyers and sellers, and it typically breaks in the direction of the prevailing move — here, higher. Today’s +6.95% candle pushed price through the upper rail and tagged $8.80 intraday, the clearest sign yet that buyers have absorbed the overhead supply the descending trendline had been feeding them. The honest nuance: the close ($8.46) settled a notch below the $8.80 high, so the breakout is underway but not yet sealed on a closing basis — which is exactly why the setup waits for a decisive push above ~$8.80 before committing. Volume is turning up on the move, but a fuller expansion on follow-through would firm the conviction behind the break. Cleared and held, the upper trendline flips from ceiling to floor, reframing the year’s grind as accumulation rather than distribution.

IBRX – Daily Chart

#2 Price Above 50-day and 200-day SMAs: IBRX is trading above both its 50-day ($7.75) and 200-day ($6.84) SMAs, with the 50-day stacked cleanly above the 200-day — the golden-cross alignment that confirms momentum favors buyers across both the short- and longer-term horizons. Both averages are sloping higher, which matters: rising MAs beneath a breakout mean the trend structure is pulling price up, not merely trailing it. The two now define a tiered support shelf — first the 50-day near $7.75, then the 200-day near $6.84 — giving buyers layered levels to defend on any retest. What ties this to Signal #1 is location: the triangle is breaking out from directly above these rising averages, so the structural trigger and the trend backdrop are pointing the same way rather than fighting each other. Price sits only ~9% above the 50-day, so the stock is advancing without being stretched — there’s separation to work with before extension becomes a concern.

#3 MACD Bullish Crossover: The daily MACD line (0.1160) has crossed above its signal line (0.1068), flipping the histogram positive (+0.0092) and confirming a fresh bullish crossover. What gives this read quality is where it’s firing — right at the zero line rather than deep in negative territory or far above it. A cross near zero catches momentum as it inflects from neutral to positive, the highest-value window for the signal, versus a deeply negative cross (early but noisy) or a stretched cross well above zero (late confirmation). The timing is the tell: the crossover is printing as price clears the triangle, so the oscillator is corroborating the breakout rather than diverging from it. With the histogram expanding off the flip, the spread between short- and long-term momentum is widening — the mechanical signature of a trend beginning to accelerate rather than stall.

#4 Bullish ADX & DI Configuration: The directional read is firmly constructive: +DI (27.83) sits well above –DI (12.06), locating trend control squarely with the buyers. The ADX line (27.52) has climbed off its lower base to sit just beneath +DI — and because it now reads above the 25 threshold that separates trending from directionless markets, it’s telling us this isn’t chop, it’s a genuine trend gaining traction. The key distinction is the trajectory: ADX has lifted from below the –DI line up toward +DI, and that path — rather than the absolute level — is what signals accelerating momentum behind an emerging move. Stacked against the MACD crossover in Signal #3, both momentum reads point the same direction, and that alignment is what elevates this from a lone indicator to a confluence. With ADX near 27 rather than pinned in the 40s–50s, the trend is confirmed but not yet mature — leaving runway before strength readings start flagging exhaustion.

#5 Reclaimed Support With Price Above Weekly MAs: Zooming out to the weekly reframes the daily breakout within a larger structure. IBRX has pushed back above a resistance-turned-support level near $7.72 (the pink dotted line) — the kind of polarity flip the market genuinely respects, because a level that inverts roles has demonstrably absorbed supply and is now attracting demand. Reinforcing that floor, price is trading well above both the 50-week ($6.13) and 200-week ($4.29) SMAs, with the 50-week above the 200-week — the same golden alignment seen on the daily, now confirmed one timeframe up. This is the multi-timeframe point that matters: when the daily and weekly structures agree, the signal carries more weight than either alone, and here the daily triangle breakout is launching from a base the weekly chart has already validated. The reclaimed $7.72 support also sits close to both the $8.80 trigger and the $7.20 stop, giving the setup a tight, well-defined structural spine.

IBRX – Weekly Chart

#6 Bullish RSI: The weekly RSI (58.92) is holding above the 50 midline and above its own signal average (56.24) — a two-part bullish read that outweighs either component alone. Clearing 50 hands the momentum advantage to buyers on the higher timeframe; sitting above its moving average and sloping up tells us that advantage is actively expanding rather than drifting sideways. Just as important is what’s left in the tank: at ~59, RSI has clear runway to the 70 overbought line before elevated readings become a headwind, so momentum can build further without the indicator flashing stretched. An RSI parked at 50 is a coin flip; one that has crossed 50 and is still climbing with room overhead is a directional statement — and here it corroborates the weekly support reclaim in Signal #5.

#7 Bullish Stochastic: The weekly stochastic has %K (61.36) crossed above %D (50.85) and is lifting out of the mid-range — a momentum handoff to buyers that carries added weight on the weekly timeframe, where the crossover filters out the intraweek noise that muddies daily reads. The location is what makes it high-quality: the cross is firing from the middle of the range, not from overbought territory, so there’s room for the signal to develop before exhaustion risk enters the frame — mid-range crossovers within an established uptrend are worth more than the oversold-bounce variety. With %K well below the 80 overbought line, the higher-timeframe momentum picture still has slack to run. Stacked alongside the weekly RSI (Signal #6) and the reclaimed support (Signal #5), all three weekly reads line up behind the daily breakout — the cleanest version of multi-timeframe confluence this setup offers.

Risks to Consider

Even strong setups can fail, especially in a catalyst-driven biotech like ImmunityBio. A few things could knock the stock off course:

• A breakdown back below the symmetrical triangle support on heavy volume would invalidate the breakout thesis
• Negative company-specific news or broader market weakness — any sector rotation out of small- and mid-cap biotech would pressure the entire group
• Continued dilution risk from ATM issuance — ImmunityBio raised $147.2 million through its at-the-market program in H1 2026, with roughly $349.2 million of capacity remaining at quarter-end
• Complex capital structure — a $480 million related-party convertible note plus a $415.1 million revenue-interest liability create significant financing obligations, with revenue-interest payments consuming 5.625%–12.5% of qualifying worldwide net sales under the current tier structure
• BCG supply dependency — ANKTIVA’s U.S. bladder regimen requires BCG, and the Tokyo-172 alternative is not yet U.S.-approved, so the supply bottleneck is not fully resolved
• Clinical and regulatory execution risk — the January 6, 2027 papillary-only PDUFA is a binary FDA decision, and QUILT-2.005 has not yet disclosed final efficacy results; failure, delay, or a restrictive label could materially reset expectations
• Regulatory compliance overhang — the FDA issued ImmunityBio a March 13, 2026 warning letter flagging certain ANKTIVA promotional communications as false or misleading; this was a promotional-compliance action rather than a clinical hold, but it raises scrutiny around broader cancer claims
• Founder/control concentration — Patrick Soon-Shiong beneficially owned approximately 64.8% of IBRX as of the July 31, 2026 Schedule 13D/A, giving the founder and affiliated entities substantial voting and economic influence
• Competition intensifying in the NMIBC treatment landscape as additional bladder-preserving therapies reach physicians, which could pressure ANKTIVA’s future share and pricing

The Bottom Line

IBRX is breaking out of a multi-month symmetrical triangle on the daily chart while reclaiming a key resistance-turned-support level and holding above rising 50-week and 200-week moving averages on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: record Q2 2026 net product revenue of $50.7 million (+92% YoY), marking the eighth consecutive quarter of sequential growth, an FDA-accepted supplemental BLA with a January 6, 2027 PDUFA date that could expand ANKTIVA into a distinct new bladder-cancer patient population, and a positive independent-committee power determination on the fully enrolled QUILT-2.005 trial, with a further sBLA submission targeted for Q4 2026.

Combine that with multiple commercial and regulatory catalysts staggered through the back half of 2026 and into early 2027 — Q3 earnings in early November, the QUILT-2.005 BCG-naïve sBLA submission in Q4, the January 6, 2027 FDA PDUFA decision, continued European and MENA commercialization, and progress on the Tokyo-172 BCG regulatory pathway — and IBRX looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our exact entry level, both price targets that imply 36%–59% potential upside, and the stop-loss we’re using to manage the downside.

Recommended Trade Setup

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $1.60 per share, the target rewards are about $3.20 and $5.20 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If IBRX drops to or below the $7.20 stop-loss before the $8.80 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.

Happy Trading!
Tara and Greg